|
|
| (15 intermediate revisions by 3 users not shown) |
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Atorvastatin#Adult Indications and Dosage]] |
| {{Abciximab}}
| |
| {{CMG}}; {{AE}} {{PB}}
| |
| | |
| ==Indications and Usage==
| |
| | |
| LIPITOR is an inhibitor of HMG-CoA reductase (statin) indicated as an adjunct therapy to diet to:
| |
| | |
| * Reduce the risk of MI, stroke, revascularization procedures, and angina in patients without CHD, but with multiple risk factors.
| |
| * Reduce the risk of MI and stroke in patients with type 2 diabetes without CHD, but with multiple risk factors.
| |
| * Reduce the risk of non-fatal MI, fatal and non-fatal stroke, revascularization procedures, hospitalization for CHF, and angina in patients with CHD.
| |
| * Reduce elevated total-C, LDL-C, apo B, and TG levels and increase HDL-C in adult patients with primary hyperlipidemia (heterozygous familial and nonfamilial) and mixed dyslipidemia.
| |
| * Reduce elevated TG in patients with hypertriglyceridemia and primary dysbetalipoproteinemia.
| |
| * Reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia (HoFH).
| |
| * Reduce elevated total-C, LDL-C, and apo B levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia after failing an adequate trial of diet therapy .
| |
| | |
| ===Limitations of Use===
| |
| | |
| LIPITOR has not been studied in Fredrickson Types I and V dyslipidemias.
| |